Mono Pharmacare
: MONOPHARMA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Mono Pharmacare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mono Pharmacare Limited is a pharmaceutical distribution and supply company established in 1994. The firm offers a diverse portfolio of products, including antibiotics, nutraceuticals, analgesics, and cardiac-diabetic medicines.
Business Model
The company operates as a distributor and supplier, generating revenue through the procurement and wholesale distribution of a wide array of pharmaceutical and healthcare products.
Growth Outlook
Growth is driven by the expansion of its pharmaceutical product distribution network and the increasing demand for diverse healthcare and nutraceutical offerings in the Indian market.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and licensing requirements that may impact operations if standards are not met.
- Supply Chain Dependency. As a distributor, the company relies heavily on the timely supply of medicines from manufacturers, making it vulnerable to supply chain disruptions.
- Market Competition. The pharmaceutical distribution sector is highly fragmented and competitive, which may exert pressure on profit margins.
- Price Controls. Government-mandated price caps on essential medicines can limit the pricing power and profitability of pharmaceutical distributors.
Start your research today
Unlock AI insights, financials, peers and live data on Mono Pharmacare and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Mono PharmacareMONOPHARMA | ₹16 Cr | — | — | — | 2.0% | — | — | -60.0% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Mono Pharmacare
: MONOPHARMA · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Mono Pharmacare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Mono Pharmacare Limited is a pharmaceutical distribution and supply company established in 1994. The firm offers a diverse portfolio of products, including antibiotics, nutraceuticals, analgesics, and cardiac-diabetic medicines.
Business Model
The company operates as a distributor and supplier, generating revenue through the procurement and wholesale distribution of a wide array of pharmaceutical and healthcare products.
Growth Outlook
Growth is driven by the expansion of its pharmaceutical product distribution network and the increasing demand for diverse healthcare and nutraceutical offerings in the Indian market.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical regulations and licensing requirements that may impact operations if standards are not met.
- Supply Chain Dependency. As a distributor, the company relies heavily on the timely supply of medicines from manufacturers, making it vulnerable to supply chain disruptions.
- Market Competition. The pharmaceutical distribution sector is highly fragmented and competitive, which may exert pressure on profit margins.
- Price Controls. Government-mandated price caps on essential medicines can limit the pricing power and profitability of pharmaceutical distributors.
Start your research today
Unlock AI insights, financials, peers and live data on Mono Pharmacare and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026